Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies

@article{Stockings2018CannabisAC,
  title={Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies},
  author={E. Stockings and G. Campbell and W. Hall and S. Nielsen and Dino Zagic and R. Rahman and B. Murnion and M. Farrell and M. Weier and L. Degenhardt},
  journal={PAIN},
  year={2018},
  volume={159},
  pages={1932–1954}
}
Abstract This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials.gov were searched in July 2017. Analyses were conducted using Revman 5.3 and Stata 15.0. A total of 91 publications containing 104 studies… Expand

Paper Mentions

Interventional Clinical Trial
Fibromyalgia is serious chronic pain condition which is often accompanied by sleep disturbances, fatigue and disability and reduced quality of life. There is no cure and… Expand
ConditionsFibromyalgia
InterventionDrug
News Article
Cannabinoids not very effective for chronic non-cancer pain
  • Dtb selecT
  • Medicine
  • Drug and Therapeutics Bulletin
  • 2019
TLDR
It seems unlikely that cannabinoids are highly effective medicines for cncp, but there was evidence that nabiximols achieved modest pain reductions as adjunctive treatments for ms-related pain. Expand
Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression
TLDR
Efficacy for neuropathic and non-neuropathic pain was similar, and pain intensity of chronic non-cancer patients was reduced by cannabinoids consumption, but effect sizes were small. Expand
Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review
TLDR
Although medical cannabis’ recognized analgesic properties make it a viable option to achieve opioid dosage reduction, the evidence from this review cannot be relied upon to promote MC as an adjunct to opioids in treating non-cancer chronic pain. Expand
Cannabinoid effects on responses to quantitative sensory testing among individuals with and without clinical pain: a systematic review.
TLDR
This systematic review critically synthesizes the evidence for cannabinoid analgesic effects on quantitative sensory testing outcomes in both healthy adults and patients with chronic non-cancer pain (CNCP) and offers recommendations for future studies to improve study rigor and reproducibility. Expand
Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: A systematic review of non-randomized studies
TLDR
There is very low certainty evidence that adverse events are common among people living with chronic pain who use medical cannabis or cannabinoids, but that few patients experience serious adverse events. Expand
Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials.
TLDR
The evidence neither supports nor refutes claims of efficacy and safety for cannabinoids, cannabis, or CBM in the management of pain. Expand
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
TLDR
There is scarce evidence to suggest that cannabinoids improve depressive disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder, or psychosis. Expand
Cannabinoids for pain or profit?
TLDR
There is currently no reliable evidence to support or refute the use of cannabis, cannabinoids, or cannabis-basedmedicine in the treatment of chronic, acute, or cancer pain, and evidence concerning the long-term implications is lacking. Expand
Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews.
TLDR
A new high-quality systematic review of randomised controlled trials is needed to critically assess the clinical evidence for cannabinoids, cannabis, or CBM in pain. Expand
Should You Recommend Cannabinoids for This Patient With Painful Neuropathy?
TLDR
An internist with a focus on addiction medicine and an addiction psychiatrist discuss how they would apply the literature to make recommendations for a patient with painful diabetic neuropathy, including counseling on both potential benefits and harms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
TLDR
A systematic review and meta-analysis of all randomized controlled trials of Cannabis-based medicines suggests that CBMs might be effective for chronic pain treatment, based on limited evidence, primarily for neuropathic pain patients. Expand
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
TLDR
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Expand
Cannabis-based medicines for chronic neuropathic pain in adults.
TLDR
To assess the efficacy, tolerability, and safety of cannabis-based medicines (herbal, plant-derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults, randomised, double-blind controlled trials are selected. Expand
Cannabinoids for fibromyalgia.
TLDR
The primary outcomes in this review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverseEvents (safety). Expand
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
TLDR
In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed. Expand
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
TLDR
Treatment with cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale, but objective improvement in mobility and patients' opinion of an improvement in pain suggest cannabinoids might be clinically useful. Expand
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).
TLDR
There was a higher rate of adverse events among cannabis users compared with controls but not for serious adverse events at an average dose of 2.5 g herbal cannabis per day, which appears to have a reasonable safety profile. Expand
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.
TLDR
This novel Bayesian meta-analysis of individual patient data from 5 randomized trials suggests that inhaled cannabis may provide short-term relief for 1 in 5 to 6 patients with neuropathic pain. Expand
Cannabis in painful HIV-associated sensory neuropathy
TLDR
Smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain from HIV-associated sensory neuropathy and the findings are comparable to oral drugs used for chronic Neuropathic pain. Expand
Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.
TLDR
An overview of the occurrence and nature of adverse events associated with any opioid agent used on a medium- or long-term basis for the treatment of CNCP in adults to complements the overview entitled 'High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews'. Expand
...
1
2
3
4
5
...